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Among 53 Acinetobacter baumannii isolates collected in 2004, nine imipenem-resistant iso-
lates were obtained from clinical specimens taken from patients hospitalized in Busan, 
Korea. Nine carbapenemase-producing isolates were further investigated in order to deter-
mine the mechanisms underlying resistance. These isolates were then analyzed via antibiotic 
susceptibility testing, microbiological tests of carbapenemase activity, pI determination, 
transconjugation test, enterobacterial repetitive consensus (ERIC)-PCR, and DNA 
sequencing. One outbreak involved seven cases of infection by A. baumannii producing 
OXA-23 β-lactamase, and was found to have been caused by a single ERIC-PCR clone. 
During the study period, the other outbreak involved two cases of infection by A. 
baumannii producing IMP-1 β-lactamase. The two clones, one from each of the outbreaks, 
were characterized via a modified cloverleaf synergy test and an EDTA-disk synergy test. 
The isoelectric focusing of the crude bacterial extracts detected nitrocefin-positive bands  
with pI values of 6.65 (OXA-23) and 9.0 (IMP-1). The PCR amplification and characteri-
zation of the amplicons via direct sequencing showed that the clonal isolates harbored 
blaIMP-1 or blaOXA-23 determinants. The two clones were characterized by a multidrug resist-
ance phenotype that remained unaltered throughout the outbreak. This resistance 
encompassed penicillins, extended-spectrum cephalosporins, carbapenems, monobactams, 
and aminoglycosides. These results appear to show that the imipenem resistance observed 
among nine Korean A. baumannii isolates could be attributed to the spread of an IMP-1- 
or OXA-23-producing clone. Our microbiological test of carbapenemase activity is a simple 
method for the screening of clinical isolates producing class D carbapenemase and/or class 
B metallo-β-lactamase, in order both to determine their clinical impact and to prevent 
further spread.
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Acinetobacter baumannii has emerged as a primary 
nosocomial pathogen in hospital outbreaks, and is 
ranked second after Pseudomonas aeruginosa among 
nosocomial aerobic nonfermentative gram-negative 
bacillar pathogens (Schreckenberger and Graevenitz, 
1999; Simor et al., 2002). A. baumannii causes respi-
ratory and urinary tract infections, as well as meningitis, 
endocarditis, burn infections, and wound sepsis, espe-
cially in intensive care units (ICUs) (Chastre and 
Trouillet, 2000). A. baumannii infections often prove 
difficult to eradicate due to high-level resistance to a 
host of antibiotics as the result of both intrinsic and 
acquired mechanisms. β-Lactamase production is the 
most salient mechanism of acquired β-lactam resist-
ance in gram-negative pathogens (Yong et al., 2003). 
Carbapenems (e.g., imipenem and meropenem) have 
become the drugs of choice against Acinetobacter 
infections in a host of medical centers, but are being 
compromised by the emergence of carbapenem- 
hydrolysing β-lactamase (carbapenemase) of molecular 
classes B and D (Livermore, 2002; Lee and Lee, 
424 Jeong et al. J. Microbiol.
2006). The class B carbapenemases thus far detected 
in Acinetobacter spp. include a variety of IMP- and 
VIM-type metallo-β-lactamases (http://www.lahey.org/ 
studies/webt.asp), but the majority of Acinetobacter 
spp. produce zinc-independent members of the molec-
ular class D β-lactamases (Afzal-Shah et al., 2001). 
The sequenced carbapenemases of this latter class 
from that species include three distinct clusters, as 
follows: (i) OXA-23-like cluster (OXA-23, -27 and 
-49) (Donald et al., 2000; Afzal-Shah et al., 2001; 
Bonnet et al., 2002; Brown et al., 2004), (ii) OXA- 
24-like cluster (OXA-24, -25, -26 and -40) (Bou et 
al., 2000; Afzal-Shah et al., 2001; Héritier et al., 
2003) and (iii) OXA-48-like cluster (OXA-48 and 
-54) (Poirel et al., 2004). OXA-23 and OXA-27 show 
99% amino acid identity, but exhibit only 60% 
identity with the amino acid sequences of the OXA- 
24-like cluster. OXA-48 shares an amino acid identity 
of 92% with OXA-54, but was only weakly related to 
other class D β-lactamases, showing an amino acid 
identity of less than 46% with any other OXA-type β
-lactamase. Recently, new subclasses of metallo-β
-lactamases have been reported, including SPM-1 and 
GIM-1 (Castanheira et al., 2004). GES-2, GES-4 and 
GES-5 class A β-lactamases show weak imipenem 
hydrolysis (Wachino et al., 2004; Jeong et al., 2005).
  Fifty-three A. baumannii isolates were collected 
from 53 patients with suspected nosocomial infections. 
The primary objective of the present study was to 
investigate an outbreak of imipenem-resistant A. bau-
mannii in the Republic of Korea, and to characterize 
the mechanisms underlying the imipenem resistance 
evidenced by the outbreak isolates.
Materials and Methods
Bacterial strains
A total of 53 nonrepetitive clinical isolates of A. 
baumannii were obtained between June 1st, 2004 and 
November 30th, 2004 at the Kosin University Gospel 
Hospital (Busan, Republic of Korea), a facility with 
1,300 beds. These isolates were collected from 
different patients hospitalized in the intensive care 
unit (ICU) and in the general (i.e., neurology and 
urology) wards. The isolates were identified via con-
ventional techniques (Schreckenberger and Graevenitz, 
1999) and/or using the Vitek GNI card (bioMérieux 
Vitek Inc., USA). A. baumannii YMC02/8/ P535 (Young 
et al., 2003) was utilized as the recipient strain for 
transfer via transconjugation. Escherichia coli ATCC 
25922 was used as the quality control strain for the 
susceptibility tests.
Susceptibility of β-lactams
Antibiotic susceptibility was evaluated via disk dif-
fusion tests, which were conducted in accordance with 
the manufacturer’s instructions using BBL (USA) disks 
impregnated with amikacin (30 μg), gentamicin (10 
μg), tobramycin (10 μg), tetracycline (30 μg), 
trimethoprim-sulfamethoxazole (1.25 and 23.75 μg, 
respectively), ciprofloxacin (5 μg), ampicillin (10 μg), 
ampicillin-sulbactam (10 and 10 μg, respectively), 
piperacillin (100 μg), piperacillin-tazobactam (100 and 
10 μg, respectively), cefoxitin (30 μg), cefotetan (30 
μg), ceftazidime (30 μg), cefotaxime (30 μg), cefepime 
(30 μg), aztreonam (30 μg), imipenem (10 μg), and 
meropenem (10 μg). The disks were dispensed using 
a BBL Sensi-Disc 12-place dispenser. MICs were 
determined via agar dilution on Muller-Hinton agar 
plates (Becton-Dickinson, USA) containing two-fold 
serially-diluted β-lactams, as described previously 
(NCCLS 2003).
Microbiological tests of carbapenemase activity
In order to characterize imipenem inactivation by the 
A. baumannii OXA-type β-lactamase, we conducted a 
microbiological disk synergy test. The cloverleaf test 
of Hornstein et al. (1997) was modified by substituting 
E. coli ATCC 25922 for the imipenem-susceptible 
Micrococcus luteus. The surface of a Muller-Hinton 
agar plate was inoculated evenly using a cotton swab 
with an overnight culture suspension of E. coli, which 
was adjusted to the turbidity of the McFarland no. 0.5 
tube. After a brief drying procedure, an imipenem 
disk (30 μg) was positioned at the center of the plate, 
and the imipenem-resistant test strains from the over-
night culture plates were streaked from the edge of 
the disk to the periphery of the plate. The presence of 
a distorted inhibition zone after overnight incubation 
was interpreted as a positive modified cloverleaf 
synergy test, revealing imipenem had been inactivated 
by carbapenemase (class B and/or D). 
  The microbiological testing of metallo-β-lactamase 
activity was conducted via an EDTA-disk synergy test 
(Lee et al., 2000), modified as follows: An overnight 
culture of the test strain was suspended to the 
turbidity of the McFarland no. 0.5 tube, and utilized 
to swab the inoculate on a Muller-Hinton agar plate. 
After drying, a 30 μg imipenem disk (BBL) and a 
blank filter paper disk were positioned 15 mm apart 
from edge to edge, and 10 μl of 0.5 M EDTA sol-
ution was then applied to the blank disk, resulting in 
a ca 1.5 mg/disk. After overnight incubation, the 
presence of an enlarged inhibition zone was interpreted 
as a positive EDTA-disk synergy test, revealing the 
inactivation of metallo-β-lactamase (class B) activity 
by EDTA. 
Plasmid preparation and Southern blot analysis
The isolation of plasmid DNA from A. baumannii 
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Table 1. Nucleotide sequences of oligonucleotides used for PCR amplifications and sequencing of blaIMP-, blaVIM-, blaGIM-, blaSPM-, blaOXA-, 
and blaGES-type genes
Primer 
(orientation)a Sequence (5'→3') Target β-lactamase Accession no. of bla
b
IMP-1F (F) GCTACCGCAGCAGAGTCTTTG
IMP-1, IMP-3, IMP-6, IMP-10 S71932, AB010417, AB040994, AY074433IMP-1R (R) CCTTTAACCGCCTGCTCTAATG
IMP-2F (F) ATGTTACGCAGCAGGGCAG
IMP-2, IMP-8, IMP-10, IMP-12, IMP-13 AJ243491, AF322577, AY074433, AJ420864, AJ550807IMP-2R (R) ATGCTCAGTCATGAGGCGC
IMP-4F (F) GAAGGCGTTTATGTTCATACTTCG
IMP-4, IMP-5, IMP-7, IMP-9 AF244145, AF290912, AF318077, AY033653IMP-4R (R) GCGTCACCCAAATTACCTAGACC
IMP-11F (F) GAGAAGCTTGAAGAGGGTGTTTAT






IMP-19, IMP-20 AB201265, AB196988
IMP-19R (R) CAGCCTGTTCCCATGTACG
VIM-1F (F) GTTTGGTCGCATATCGCAAC
VIM-1, VIM-4, VIM-5, VIM-7, VIM-11 Y18050, AY135661, AY144612, AJ536835, AY635904VIM-1R (R) AGACCGCCCGGTAGACC
VIM-2F (F) GTTTGGTCGCATATCGCAAC VIM-2, VIM-3, VIM-6, VIM-8, VIM-9, 
VIM-10
AF191564, AF300454, AY165025, 








OXA-23, OXA-27, OXA-49 AJ132105, AF201828, AY288523
OXA-23R (R) TGTCAAGCTCTTAAATAATATTCAGC
OXA-24F (F) GATGAAGCTCAAACACAGGGTG OXA-24, OXA-25, OXA-26, OXA-40, 
OXA-72
AJ239129, AF201826, AF201827, 
AF509241, AY739646OXA-24R (R) TTAAATGATTCCAAGATTTTCTAGC
OXA-48F (F) GATTATCGGAATGCCTGCGG
OXA-48, OXA-54 AY236073, AY500137
OXA-48R (R) CTACAAGCGCATCGAGCATCA
GES-F (F) GTTAGACGGGCGTACAAAGATAAT GES-1, GES-2, GES-3, GES-4, IBC-1, 
IBC-2
AF156486, AF326355, AB113580, 
AB116260, AF208529, AF329699GES-R (R) TGTCCGTGCTCAGGATGAGT
aOrientation of each primer: F, forward; R, reverse.
bβ-lactamase genes (bla) used in the multiple sequence alignment for designing each primer pair.
clinical isolates was conducted as described by 
Sambrook and Russel (2001), using plasmid-safe ATP- 
dependent DNase (Epicentre Technology, USA) for 
the removal of contaminated bacterial chromosomal 
DNA. The prepared plasmids were separated on 1.0% 
agarose using a field inversion gel electrophoresis 
(FIGE) Mapper Electrophoresis System (Bio-Rad, 
USA). 
  DNA was transferred to nylon membrane (Hybond- 
N; Amersham International, England) essentially as 
described by Sambrook and Russell (2001). Labeling 
of the DNA (PCR products for blaIMP and blaOXA genes) 
probes was conducted using digoxigenin, as described by 
the manufacturer (Boehringer Mannheim Biochemicals, 
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IN). Hybridization was conducted at 68°C with the 
buffers recommended in the manual of the digox-
igenin kit purchased from Boehringer Mannheim 
Biochemicals.
Transconjugation experiments
Curing was attempted via the overnight growth of the 
cultures in nutrient broth containing ethidium bromide 
(Sigma-Aldrich, USA) at 0.25-0.5 times the MIC, 
followed by replica plating onto Muller-Hinton agar 
plates, with and without imipenem at concentrations 
of 2 μg/ml or 10 μg/ml. The transconjugation experi-
ments were conducted as described previously (Oh et 
al., 2003), using a rifampin-resistant A. baumannii 
YMC02/8/P535 as the recipient. The transconjugants 
were selected on Muller-Hinton agar supplemented 
with rifampin (Sigma, USA) (100 μg/ml) to inhibit 
the growth of the donor strain, and with imipenem (1 
μg/ml) to inhibit the growth of the recipient strain. 
Isoelectric focusing analysis
The crude bacterial extracts were acquired from A. 
baumannii clinical isolates after the centrifugation of 
the sonicated culture, as described previously (Lee et 
al., 2002). Sonic extracts were employed in the 
determination of isoelectric points (pIs) and β- 
lactamase activity. Isoelectric focusing (IEF) was 
conducted on Ready Gel precast IEF polyacrylamide 
gels (Bio-Rad, USA) as described previously (Lee et 
al., 2002). Gels were developed with 0.5 mM 
nitrocefin (Merck, USA).
PCR amplification and DNA sequencing
Unless stated otherwise, molecular biological reagents 
and restriction enzymes were acquired from Sigma- 
Aldrich. The genomic DNA of the clinical isolates was 
prepared using a Wizard Genomic DNA Purification 
Kit (Promega, USA), and used as template DNA in 
the PCR amplification procedure. The PCR 
amplification primers were designed via the selection 
of consensus sequences in the multiple-nucleotide 
alignment of IMP-type β-lactamase genes (blaIMP), 
VIM-type β-lactamase genes (blaVIM), GIM-1 β- 
lactamase gene (blaGIM-1), SPM-1 β-lactamase gene 
(blaSPM-1), OXA-type β-lactamase genes (blaOXA) and 
GES-type β-lactamase genes (blaGES), using the 
Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer
3/primer3_www.cgi). The primers are described in 
Table 1. PCR amplifications were conducted as de-
scribed previously (Lee et al., 2000, 2001, 2005b; 
Jeong et al., 2003, 2004; Song et al., 2005, 2006).
  DNA sequencing was conducted via direct sequenc-
ing, using an automatic sequencer (ABI PRISM3100; 
Applied Biosystems, Germany), as described previously 
(Lee et al., 2001). DNA sequence analysis was per-
formed using DNASIS for Windows (Hitachi Software 
Engineering America Ltd., USA). Database similarity 
searches for both the nucleotide sequences and the 
deduced protein sequences were conducted via 
BLAST at the National Center for Biotechnology 
Information website (http:// www.ncbi.nlm.nih.gov).
Enterobacterial repetitive consensus PCR
Enterobacterial repetitive consensus (ERIC)-PCRs were 
conducted in 50 μl volumes, each containing 10 ng of 
genomic DNA from the A. baumannii clinical isolates, 
4 mM MgCl2, 50 pM of each primer: ERIC1R (5'- 
ATGTAAGCTCCTGGGGATTCAC-3') and ERIC2 (5'- 
AAGTAAGTGACTGGGGTGAGCG-3') (Versalovic et 
al., 1991), 1.25 U of TaKaRa Ex Taq polymerase 
(TaKaRa, Japan), 0.2 mM of each dATP, dCTP, dGTP 
and dTTP in 25 mM TAPS [N-Tris(hydroxy)methyl- 
3-amino-propane sulfonic acid pH 9.3], 50 mM KCl, 
and 1 mM 2-mercaptoethanol. Amplification was car-
ried out with the following program: 95°C for 5 min 
followed by 35 cycles of 1 min at 52°C, 5 min at 
70°C, and 1 min at 92°C. A final extension step was 
run at 70°C for 10 min. The amplified products (10 
μl aliquots) were analyzed in 2% Seakem LE agarose 
(BMA, USA). For pulsed-field gel electrophoresis 
(PFGE), the SmaI-digested genomic DNA was prepared 
in accordance with the instructions provided by 
Bio-Rad (USA), and the fragments were separated for 
20 h at 6 V/cm at 11°C, using a CHEF-DRII system 
(Bio-Rad), with initial and final pulse times of 0.5 
and 60 sec, respectively. DNA fingerprints were in-
terpreted in accordance with the recommendations of 
Zarrilli et al. (2004).
Results
Phenotypic properties of imipenem-resistant isolates
Thirty-one (59%), 15 (28%), five (9%) and two (4%) 
among 53 nonrepetitive A. baumannii isolates were 
recovered from ICU, urology ward and neurology 
ward, respectively. 26 (49%), 21 (40%), four (7%) 
and two (4%) isolates among a total of 53 were 
obtained from sputum, urine, pus, and blood samples, 
respectively. This result shows that sputum and urine 
may be more important sources of spread than are 
pus and blood. The results of our antimicrobial 
susceptibility testing of 53 isolates revealed that the 
prevalences of resistance to ampicillin, cefoxitin, 
cefotetan and aztreonam were high (94.3, 86.8, 94.3 
and 64.2%, respectively). The prevalence of isolates 
resistant to all other tested antimicrobial agents was 
determined to be less than 26.4% (see Table 2). We 
detected a significant amount (17.0%, 9 of 53) of 
imipenem-resistant isolates. In Korea, the incidence of 
imipenem resistance among A. baumannii from June 
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Table 2. Antimicrobial susceptibility of A. baumannii isolates
Antimicrobial agent
Resistance (%)a
IMP-S (n=44) IMP-R (n=9) Total (n=53)
Ampicillin 93.2 100 94.3
Ampicillin-sulbactam 0 22.2 3.8
Piperacillin 2.3 100 17.0
Piperacillin-tazobactam 2.3 100 13.2
Cefoxitin 86.4 88.9 86.8
Cefotetan 97.9 77.8 94.3
Ceftazidime 4.5 100 18.9
Cefotaxime 13.6 100 26.4
Cefepime 2.3 100 15.1
Aztreonam 63.6 100 64.2
Imipenem 0 100 17.0
Meropenem 0 100 17.0
Amikacin 6.8 88.9 20.8
Gentamicin 9.1 88.9 22.6
Tobramycin 9.1 88.9 22.6
Tetracycline 6.8 55.6 15.1
Trimethoprim-sulfamethoxazole 11.4 55.6 18.9
Ciprofloxacin 4.5 77.8 17.0
aIMP-S, imipenem-susceptible; IMP-R, imipenem-resistant.
Fig. 1. Modified cloverleaf test results for a representative 
OXA-23-producing isolate (A. baumannii K0420859) (A), an 
imipenem-susceptible isolate producing neither IMP-1 nor OXA-23
(A. baumannii K0420039) (B), a representative IMP-1-producing 
isolate (A. baumannii K0420673) (C), and a negative control (A. 
baumannii ATCC 19606) (D). A Mueller-Hinton agar plate was 
incubated with E. coli ATCC 25922. An imipenem disk was 
positioned in the center, and test isolates were streaked from the 
edge of the disk to the periphery of the plate, followed by 
overnight incubation. 
to September 2004 was lower than the incidence 
(26.9%) in 2003, which may be the result of a 
reduction in the prescription of imipenem, as well as 
the generally more judicious use of imipenem (Jeon et 
al., 2005; Lee et al., 2005a). A total of nine imipenem- 
resistant A. baumannii isolates were analyzed via the 
modified cloverleaf synergy test and the EDTA-disk 
synergy test. Metallo-β-lactamase generation (EDTA- 
disk synergy test positive) was detected in two 
isolates. The prevalence of carbapenemase-producing 
isolates (modified cloverleaf synergy test positive) 
was 100% (9 of 9) (see Fig. 1 and Table 3). These 
results were confirmed with the carbapenemase activ-
ity data via spectrophotometric assays, in the presence 
and absence of EDTA. These results indicate that two 
imipenem-resistant A. baumannii isolates do produce 
class B metallo-β-lactamases, and seven isolates pro-
duce other type β-lactamases. Nine β-lactamase-pro-
ducing A. baumannii showed high levels of resistance 
to ampicillin, piperacillin, piperacillin-tazobactam, cef-
tazidime, ceftazidime-clavulanic acid, cefepime, imi-
penem, and meropenem (see Table 3). All nine β- 
lactamase-producing A. baumannii isolates only evi-
denced intermediate resistance to ampicillin-sulbactam, 
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Table 3. Characterization of imipenem-resistant A. baumannii isolates 
Isolate Age/Sex Type of specimen Ward
c
MICs (μg/ml) of β-lactamsc
β-Lactamase
Synergy test
AMP SAM PIP TZP CAZ CAZ-CLA FEP IMP MEM Cloverleaf EDTA-disk
K0420673 71/M Urine NW >256 16 >256 >256 >256 >256 128 32 32 IMP-1 + +
K0421793 46/M Urine NW >256 16 >256 >256 >256 >256 256 32 64 IMP-1 + +
K0420859 65/F Urine NW >256 16 >256 128 256 256 32 16 16 OXA-23 + –
K0418396 61/F Pus NW >256 16 >256 128 256 256 64 16 16 OXA-23 + –
K0418480 64/M Sputum ICU >256 32 >256 128 256 256 64 16 16 OXA-23 + –
K0418919 72/F Sputum ICU >256 16 >256 128 256 256 64 32 16 OXA-23 + –
K0419543 79/M Sputum ICU >256 16 >256 128 >256 >256 64 32 16 OXA-23 + –
K0419583 56/F Sputum NW >256 16 >256 128 >256 >256 64 16 16 OXA-23 + –
K0425685 1/M Urine UW >256 16 >256 128 256 256 32 16 16 OXA-23 + –
K0420039a 58/F Sputum NW >256 16 >256 64 >256 >256 >256 1 1 NDb – –
aImipenem-susceptible strain.
bND, not detectable for carbapenemase.
cAbbreviation: AMP, ampicillin; SAM, ampicillin-sulbactam (2:1 ratio of β-lactam to inhibitor); PIP, piperacillin; TZP, piperacillin- 
tazobactam (inhibitor fixed at 4 μg/ml); CAZ, ceftazidime; CAZ-CLA, ceftazidime-clavulanic acid (inhibitor fixed at 4 μg/ml); FEP, 
cefepime; IMP, imipenem; MEM, meropenem; ICU, intensive care unit; NW, neurology ward; UW, urology ward.
relative to the other tested antibiotics. Two EDTA- 
disk and modified cloverleaf synergy test positive 
isolates were shown to produce β-lactamase with an 
apparent pI of 9.0, and seven modified cloverleaf 
synergy test positive isolates produced a β-lactamase 
with an apparent pI of 6.65 (data not shown). On the 
basis of the IEF results, as well as on the results of 
previous studies of IMP-1-producing P. aeruginosa 
(Laraki et al., 1999) and OXA-23-producing A. 
baumannii (Donald et al., 2000) and Proteus mirabilis 
(Bonnet et al., 2002), we suspected that the IMP-1 
(class B) and OXA-23 (class D) carbapenemases 
might be relevant to imipenem resistance.
Molecular characterization of IMP-1 or OXA-23- 
producing A. baumannii isolates
Neither the transfer nor the curing of imipenem 
resistance was achieved with any of the imipenem- 
resistant isolates, despite multiple attempts. blaIMP-1- 
or blaOXA-23-carrying plasmid DNA was apparently 
undetectable, either in plasmid preparation without 
contaminated bacterial chromosomal DNA by plas-
mid-safe ATP-dependent DNase, or in the whole 
genomic DNA preparations from nine isolates. In a 
Southern blot experiment conducted with the genomic 
DNA of nine of the isolates, the blaIMP-1 and blaOXA-23 
probes were hybridized to the band of chromosomal 
DNA. Nine clinical isolates yielded PCR products 
with primer pairs for the blaIMP-1 and blaOXA-23 genes, 
but not with other primer pairs for blaVIM, blaGIM, 
blaSPM, blaGES, blaOXA-24 and blaOXA-48. Considering the 
resistance phenotypes of the nine clinical isolates, the 
resistance genotypes of these isolates were analyzed 
via the direct sequencing of the PCR-amplified 
fragments specific for the blaIMP-1 and blaOXA-23 genes. 
The DNA sequences of the PCR-amplified fragments 
specific for the blaIMP-1 and blaOXA-23 genes were 
found to be identical to the entire sequences for the 
blaIMP-1 (GenBank accession number S71932) and 
blaOXA-23 (GenBank accession number AJ132105) 
genes, respectively. Based on the DNA sequencing 
results, two EDTA-disk synergy test positive and 
seven modified cloverleaf synergy test positive 
clinical isolates were determined to harbor the blaIMP-1 
gene and the blaOXA-23 gene, respectively. The IMP-1 
and OXA-23 carbapenemases were involved in 
imipenem resistance, as described previously (Donald 
et al., 2000; Dalla-Costa et al., 2003; Laraki et al., 
2004).
ERIC-PCR analysis
ERIC is a technique predicated on the analysis of 
repetitive chromosomal sequences, and has recently 
been employed in the clonal characterization of intra- 
and inter-species of Enterobacteriaceae. Dispersed 
repetitive DNA sequences within the genomes of 
bacteria, using conserved primers corresponding to the 
ERIC sequences, was also assessed via PCR. ERIC- 
PCR generated a characteristic genomic fingerprint, 
which could be used to determine intra- and inter- 
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Fig. 2. ERIC-PCR patterns of genomic DNA from nine clinical isolates of A. baumannii : K0420673 (lane 1), K0421793 (lane 2), 
K0420859 (lane 3), K0418396 (lane 4), K0418480 (lane 5), K0418919 (lane 6), K0419543 (lane 7), K0419583 (lane 8), and K0425685 
(lane 9). Lanes M1 (HindIII/EcoRI-digested phage λ) and M2 (100 bp stepwise ladder) show band patterns of DNA marker fragments 
(sizes in bp are indicated on the edge of the gel). ERIC-PCR was conducted with ERIC2 and ERIC1R primers.
species genotypic variations among the Enterobacteriaceae 
(Dalla-Costa et al., 1998), Ps. aeruginosa (Luzzaro et 
al., 2001) and A. baumannii (Luzzaro et al., 2001; Oh 
et al., 2003; Silbert et al., 2004). Nine clinical isolates, 
when evaluated via ERIC-PCR, generated distinct 
bands ranging in size from 0.1 to 35.5 kb and varying 
from 7 to 12 bands  (see Fig. 2). The ERIC-PCR fin-
gerprints of two IMP-1-producing A. baumannii 
isolates were identical. The seven OXA-23-producing 
A. baumannii isolates all evidenced identical patterns. 
Two different banding patterns were detected between 
two IMP-1-producing isolates and seven OXA-23- 
producing isolates. These results were verified by 
PFGE analysis with SmaI (data not shown).
Discussion
Since 2003, a high incidence of imipenem resistance 
has been observed among nosocomial A. baumannii 
isolates in Korea. Therefore, the objective of this 
study was to determine whether this resistance was 
the result of the dissemination of an imipenem 
resistance determinant, and/or the spread of one A. 
baumannii clone. Microbiological assays indicated 
that imipenem was deactivated by seven imipenem- 
resistant A. baumannii isolates. No alterations in 
carbapenemase activity were detected in the presence 
of EDTA, thereby pointing to the production of a 
non-metallo-β-lactamase. OXA class D carbapene-
mases have been identified in A. baumannii collected 
in the UK (OXA-23) (Donald et al., 2000), Spain 
(OXA-24, 25 and 40) (Bou et al., 2000; Donald et 
al., 2000; Afzal-Shah et al., 2001; Héritier et al., 
2003), Belgium (OXA-26) (Silva et al., 2004) and 
Singapore (OXA-27) (Silva et al., 2004). A. baumannii 
is a nosocomial pathogen which is emerging, in part, 
as the consequence of the capacity of the pathogen to 
acquire resistance against multiple antimicrobial agents. 
As OXA-23-producing A. baumannii strains confer 
resistance against the majority of β-lactams, including 
imipenem, aztreonam, ceftazidime, and cefepime, a 
limited number of antimicrobial agents, including pol-
ymyxin, sulbactam and minocycline, maintain reliable 
levels of activity against OXA-23-producing A. 
baumannii  (Dolla-Costa et al., 2003). However, the 
results of our studies showed that 85.7% of OXA-23- 
producing A. baumannii isolates evidenced an inter-
mediate degree of resistance against ampicillin- 
sulbactam. Thus, it is important to monitor and control 
the spread of OXA-23-producing A. baumannii, which 
is resistant to most β-lactams. Two isolates produced 
a β-lactamase with an apparent pI of 9.0. On the 
basis of the IEF results, as well as previous reports 
regarding IMP-1-producing A. baumannii in Italy 
(Riccio et al., 2000), IMP-1 metallo-β-lactamase was 
also involved in imipenem resistance.
  We detected nine different isolates of imipenem- 
resistant A. baumannii from Korean patients. Among 
nine isolates, seven produced OXA-23. The clonal 
relatedness of A. baumannii Korean isolates was as-
sessed via ERIC-PCR. All OXA-23-producing isolates 
exhibited very similar antibiotic resistance profiles, 
and very similar DNA fingerprinting patterns. Two 
IMP-1-producing isolates evidenced identical patterns. 
Such a correspondence of phenotypic and genotypic 
characteristics can be attributed to a common clonal 
origin. Our results show that the imipenem resistance 
observed among nine Korean A. baumannii isolates is 
attributable to the spread of two IMP-1- or OXA-23- 
producing clones. A method by which metallo-β-lac-
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tamase (class B or D) could be easily type-identified 
can facilitate the control of hospital infection, and 
bolster the ability of the physician to prescribe the 
most appropriate antibiotic, thus reducing selective 
pressure and antibiotic resistance (Lee et al., 2005a). 
Our microbiological test of carbapenemase activity 
allows for such easy identification, and constitutes a 
simple method for the screening of clinical isolates 
producing class D carbapenemase and/or class B met-
allo-β-lactamase, both to determine their clinical 
impact and to prevent further spread. The clinical 
significance of these isolates, which are emerging in 
Korea, is of great importance, as clinicians have been 
advised against the use of extended-spectrum cepha-
losporins, aztreonam, imipenem, and aminoglycosides. 
This observation underlines the importance of estab-
lishing effective control measures in Asian hospitals, 
including the early detection of colonized patients, 
isolation procedures, and the judicious use of antibiotics.
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